ArticleWorld journal of hepatology2025
Advancing precision in hepatocellular carcinoma prognostication: The promise of biparametric magnetic resonance imaging-based multimodal models.
Article in World journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zuo and Liu investigated the value of a novel noninvasive approach integrating biparametric magnetic resonance imaging, radiomics, deep transfer learning, and clinical factors in predicting Ki-67 risk stratification and recurrence-free survival (RFS) in hepatocellular carcinoma (HCC). The study included 198 HCC patients and utilized histopathological Ki-67 expression as the reference standard for risk stratification. The integrated multimodal model combining radiomic features, deep transfer learning signatures, and clinical factors (nonsmooth tumor margin and absence of an enhanced capsule), achieved an area under the curve of 0.92 in the training and validation cohorts for predicting high Ki-67 risk, with a sensitivity and specificity of 0.88 and 0.85, respectively. Furthermore, the model effectively stratified RFS, with median RFS of 33.53 months in the high-risk group
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.